Abstract
The missense SNP NC_000004.12:g.102267552C>T (SLC39A8.p.(Ala391Thr), rs13107325) in SLC39A8, which encodes a zinc transporter, has been linked to schizophrenia and is the likely causal variant for one of the genome-wide association loci associated with the disorder.
We tested whether the schizophrenia-risk allele at p.(Ala391Thr) was associated with schizophrenia-related phenotypes, including positive, negative, and disorganised symptoms, cognitive ability, educational attainment, and age of psychosis onset, within three schizophrenia cohorts (combined N=1,232) and, with equivalent phenotypes, in a sample of population controls (UK Biobank, N=355,069). We used regression analyses controlling for age, sex, and population stratification.
Within the schizophrenia cohorts, after correction for multiple testing, p.(Ala391Thr) was not significantly associated with any schizophrenia-related phenotypes. In the unaffected participants from the UK Biobank, the schizophrenia-risk allele at p.(Ala391Thr) was associated with significantly poorer cognitive ability and fluid intelligence, a lower probability of obtaining GCSEs or a degree-level qualification, and fewer years in education. There was no association between p.(Ala391Thr) and self-reported psychotic experiences in this cohort.
The schizophrenia-risk allele was associated with poorer cognitive ability, but not psychotic experiences, in a volunteer sample drawn from of the general population. To determine whether p.(Ala391Thr) is associated with cognitive phenotypes in people with schizophrenia, and to understand the role of p.(Ala391Thr) in the aetiology of cognitive impairment in schizophrenia, larger independent samples are required.
Competing Interest Statement
J.H., M.C.O., M.J.O., L.W., and J.T.R.W. were investigators on the grant from Takeda Pharmaceuticals Ltd. to Cardiff University. S.E.S. and G.W. were employed on this grant. J.H. is the Chief Medical Officer for MeOmics Precision Medicine Ltd. and M.J.O is the recipient of a grant from Akrivia Health, but neither of these companies were involved in this study.
Funding Statement
This study was funded by a grant from Takeda Pharmaceuticals Ltd. to Cardiff University. Takeda Pharmaceuticals Ltd. was not involved in the design of the study or the interpretation of the results. S.E.L was supported by a grant from NIMH (Award R01MH124873) and a Medical Research Council Centre programme grant MR/P005748/1. E.F. was supported by a Wellcome Trust Integrative Neuroscience PhD Studentship (108891/B/15/Z/WT). A.F.P. was supported by the Academy of Medical Sciences Springboard award (SBF005\1083). S.E.S., A.F.P., M.C.O. and J.T.R.W. are also supported by funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964874.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CardiffCOGS was approved by the South East Wales Research Ethics Committee Panel (reference number: 07/ WSE03/110) and received HRA approval. All participants provided written informed consent. Multicentre and Local Research Ethics Committee approval was obtained for Cardiff F-Series and all participants gave written informed consent to participate. For Cardiff SibPairs written consent was obtained following local ethical approval guidelines. Ethical approval for the curation and development of DRAGON-Data was obtained from Cardiff University's School of Medicine Research Ethics Committee (Ref: 19/72). The scientific protocol of the UK Biobank (https://www.ukbiobank.ac.uk) has been reviewed and approved by the North West Multi-centre Ethics Committee. Our access to the UK Biobank data was under the project number 13310
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
To comply with the ethical and regulatory framework under which the Cardiff Schizophrenia Samples were obtained, access to individual-level data requires a collaboration agreement with Cardiff University; requests to access these datasets should be directed to J.T.R.W. (WaltersJT{at}cardiff.ac.uk) and M.J.O. (OwenMJ{at}cardiff.ac.uk). UK Biobank data is available by application to the UK Biobank (www.ukbiobank.ac.uk).
